Tolerability and Treatment Compliance with Angiotensin II Receptor Antagonists

Giuseppe Mancia, Gino Seravalle, Guido Grassi

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Several studies and intervention trials performed during the past 30 years have provided evidence that hypertension-related cardiovascular risk is not irreversible. This is because the reduction in blood pressure (BP) induced by antihypertensive drugs has been shown to be accompanied by a clear-cut decrease in the rate of cardiovascular events and complications. There is also evidence that BP control in the population is far from being optimal, and that no more than one quarter of treated hypertensive patients display BP values <140/90 mm Hg. The reasons for inadequate BP control are multiple, involving a combination of factors such as inadequate compliance with treatment, intolerance to side effects of currently prescribed drugs, and insufficient clinical use of combination drug treatment. This article focuses on three major areas. It first provides an overview of the current status of BP control in treated hypertensive persons. It then examines the factors potentially responsible for this phenomenon, with particular emphasis on the relevance of the so-called "compliance factor." Finally it provides an overview of the tolerability and compliance profile of the angiotensin II receptor antagonists, a new class of antihypertensive drugs characterized by an efficacy and safety profile.

Original languageEnglish
Pages (from-to)1066-1073
Number of pages8
JournalAmerican Journal of Hypertension
Volume16
Issue number12
DOIs
Publication statusPublished - Dec 2003

Fingerprint

Angiotensin Receptor Antagonists
Blood Pressure
Antihypertensive Agents
Compliance
Therapeutics
Drug Combinations
Hypertension
Safety
Pharmaceutical Preparations
Population

Keywords

  • Angiotensin II antagonists
  • Antihypertensive drug treatment
  • Blood pressure control
  • Compliance
  • Systolic blood pressure
  • Tolerability

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Tolerability and Treatment Compliance with Angiotensin II Receptor Antagonists. / Mancia, Giuseppe; Seravalle, Gino; Grassi, Guido.

In: American Journal of Hypertension, Vol. 16, No. 12, 12.2003, p. 1066-1073.

Research output: Contribution to journalArticle

@article{6d8e12bf600846b485abdf6df171e833,
title = "Tolerability and Treatment Compliance with Angiotensin II Receptor Antagonists",
abstract = "Several studies and intervention trials performed during the past 30 years have provided evidence that hypertension-related cardiovascular risk is not irreversible. This is because the reduction in blood pressure (BP) induced by antihypertensive drugs has been shown to be accompanied by a clear-cut decrease in the rate of cardiovascular events and complications. There is also evidence that BP control in the population is far from being optimal, and that no more than one quarter of treated hypertensive patients display BP values <140/90 mm Hg. The reasons for inadequate BP control are multiple, involving a combination of factors such as inadequate compliance with treatment, intolerance to side effects of currently prescribed drugs, and insufficient clinical use of combination drug treatment. This article focuses on three major areas. It first provides an overview of the current status of BP control in treated hypertensive persons. It then examines the factors potentially responsible for this phenomenon, with particular emphasis on the relevance of the so-called {"}compliance factor.{"} Finally it provides an overview of the tolerability and compliance profile of the angiotensin II receptor antagonists, a new class of antihypertensive drugs characterized by an efficacy and safety profile.",
keywords = "Angiotensin II antagonists, Antihypertensive drug treatment, Blood pressure control, Compliance, Systolic blood pressure, Tolerability",
author = "Giuseppe Mancia and Gino Seravalle and Guido Grassi",
year = "2003",
month = "12",
doi = "10.1016/j.amjhyper.2003.07.012",
language = "English",
volume = "16",
pages = "1066--1073",
journal = "American Journal of Hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Tolerability and Treatment Compliance with Angiotensin II Receptor Antagonists

AU - Mancia, Giuseppe

AU - Seravalle, Gino

AU - Grassi, Guido

PY - 2003/12

Y1 - 2003/12

N2 - Several studies and intervention trials performed during the past 30 years have provided evidence that hypertension-related cardiovascular risk is not irreversible. This is because the reduction in blood pressure (BP) induced by antihypertensive drugs has been shown to be accompanied by a clear-cut decrease in the rate of cardiovascular events and complications. There is also evidence that BP control in the population is far from being optimal, and that no more than one quarter of treated hypertensive patients display BP values <140/90 mm Hg. The reasons for inadequate BP control are multiple, involving a combination of factors such as inadequate compliance with treatment, intolerance to side effects of currently prescribed drugs, and insufficient clinical use of combination drug treatment. This article focuses on three major areas. It first provides an overview of the current status of BP control in treated hypertensive persons. It then examines the factors potentially responsible for this phenomenon, with particular emphasis on the relevance of the so-called "compliance factor." Finally it provides an overview of the tolerability and compliance profile of the angiotensin II receptor antagonists, a new class of antihypertensive drugs characterized by an efficacy and safety profile.

AB - Several studies and intervention trials performed during the past 30 years have provided evidence that hypertension-related cardiovascular risk is not irreversible. This is because the reduction in blood pressure (BP) induced by antihypertensive drugs has been shown to be accompanied by a clear-cut decrease in the rate of cardiovascular events and complications. There is also evidence that BP control in the population is far from being optimal, and that no more than one quarter of treated hypertensive patients display BP values <140/90 mm Hg. The reasons for inadequate BP control are multiple, involving a combination of factors such as inadequate compliance with treatment, intolerance to side effects of currently prescribed drugs, and insufficient clinical use of combination drug treatment. This article focuses on three major areas. It first provides an overview of the current status of BP control in treated hypertensive persons. It then examines the factors potentially responsible for this phenomenon, with particular emphasis on the relevance of the so-called "compliance factor." Finally it provides an overview of the tolerability and compliance profile of the angiotensin II receptor antagonists, a new class of antihypertensive drugs characterized by an efficacy and safety profile.

KW - Angiotensin II antagonists

KW - Antihypertensive drug treatment

KW - Blood pressure control

KW - Compliance

KW - Systolic blood pressure

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=0345490819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345490819&partnerID=8YFLogxK

U2 - 10.1016/j.amjhyper.2003.07.012

DO - 10.1016/j.amjhyper.2003.07.012

M3 - Article

C2 - 14643584

AN - SCOPUS:0345490819

VL - 16

SP - 1066

EP - 1073

JO - American Journal of Hypertension

JF - American Journal of Hypertension

SN - 0895-7061

IS - 12

ER -